To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes.
insulin administered to these animals (3) . These data suggest that methazolamide is a novel insulin sensitizer that is complementary to metformin. Ongoing mechanistic studies have shown that methazolamide exerts its metabolic effects by a mitochondrial mechanism distinct from CA inhibition.
RESEARCH DESIGN AND METHODS
This was a randomized, double-blind, placebo-controlled, proof-of-concept study conducted at three sites in Australia between 2010 and 2012. The protocol and amendments were approved by independent ethics committees and institutional review boards. The study was implemented according to Good Clinical Practice and the Declaration of Helsinki. All study patients gave written informed consent prior to screening.
Eligible patients included men and women between the age of 18 and 75 years with type 2 diabetes. Key inclusion criteria were a hemoglobin A 1c (HbA 1c ) at screening of 6.5-8.5% (48-69 mmol/mol), body weight .50 kg, and a BMI #40 kg/m 2 . The study included patients who were not treated with any diabetes medication (Non-MET) and patients who had been treated with metformin for at least 3 months and had a stable metformin dose for at least 8 weeks prior to study entry (MET). Metformin doses were not altered throughout the study ( Supplementary Fig. 1 ).
Patients were randomized in a 1:1 ratio to receive either methazolamide (40 mg b.i.d.) or matching placebo for 24 weeks. Blood samples for biochemistry, venous blood gases, fasting blood glucose, and insulin were taken at screening, day 0, and weeks 1, 2, 4, 8, 12, 18, and 24. HbA 1c measurements, hematology, lipid profile, and urinalysis were conducted at screening, day 0, and weeks 12 and 24. Patients were consulted by telephone at weeks 3, 10, 15, and 21, and a telephone follow-up was conducted 30 days after study completion.
The primary efficacy end point was the change in HbA 1c from baseline to 24 weeks (DHbA 1c ) in the pooled (Non-MET1MET) methazolamide group compared with the pooled placebo group (Non-MET1MET). The primary safety end point was the incidence of metabolic acidosis (based on venous blood gas parameters), defined as one of the following: pH #7.25 in repeated venous blood gas analysis and confirmed by arterial blood gas analysis, bicarbonate ,20 mmol/L, or base excess below -5.
The study was powered to demonstrate superiority of the pooled (Non-MET1 MET) methazolamide group over the pooled placebo group for the primary efficacy end point. There were insufficient patient numbers for comprehensive statistical comparisons between the Non-MET and MET groups. Statistical analyses were performed in accordance with ICH E9 guidelines using SAS, version 9.2 (SAS Institute, Cary, NC). Changes in HbA 1c , fasting blood glucose, serum alanine aminotransferase (ALT), microalbumin, and blood pressure were evaluated using repeated-measures ANCOVA with missing data imputed using a last observation carried forward strategy. Treatment group differences were estimated using least squares means and 95% CIs based on the mean square error from ANCOVA using a one-sided significance level (P , 0.05).
RESULTS
A total of 132 patients were screened, and 76 were enrolled in the study. Baseline demographic parameters and HbA 1c were well matched between groups (Table 1 and Supplementary Table 1 ). Ten patients (13%) discontinued the study: 5 placebotreated and 5 methazolamide-treated.
The clinical study achieved its protocolspecified primary efficacy end point, demonstrating a statistically significant reduction in HbA 1c from baseline to week 24 in methazolamide-treated patients relative to placebo (Table 1) . Greater reductions in HbA 1c were observed in patients with higher baseline HbA 1c , and a statistically significant regression was noted between DHbA 1c and baseline HbA 1c values in methazolamidetreated patients ( Supplementary Fig. 2 ). The proportion of patients with HbA 1c #6.5% (48 mmol/mol) increased from day 0 to week 24 in the methazolamide group but was unchanged in the placebo group (Table 1) .
Methazolamide treatment caused a significant reduction in serum ALT from baseline to week 24 compared with placebo ( Table 1) . The ALT reduction occurred as early as week 1 and continued for the duration of the study (Supplementary Fig. 2 ). There were no significant alterations to g-glutamyltransferase (mean 6 SD for placebo 1.6 6 13.4 units/L, methazolamide -1.8 6 10.4 units/L) or other liver markers.
Methazolamide-treated patients also had reduced urinary microalbumin compared with placebo at week 24 owing exclusively to microalbumin reductions in MET patients. There were no significant changes in creatinine or urea, and the incidence of abnormal renal function (defined as .10% reduction in eGFR) was similar for methazolamide (30%) and placebo (36%).
Changes in body weight were not different between the pooled methazolamide and pooled placebo groups; however, in the MET group, methazolamide-treated patients lost more body weight (-2.2 6 3.6 kg, n 5 21) than placebo-treated patients (-0.3 6 1.7 kg, n 5 18) at week 24 (P 5 0.04, ANOVA with two-sided t test). In the Non-MET group, methazolamideand placebo-treated patients lost similar amounts of body weight ( Supplementary  Fig. 3 ).
There were no incidences of hypoglycemia or hypotension and no significant effects of methazolamide on fasting blood glucose; homeostasis model assessment of insulin resistance; fasting insulin; HDL, LDL, or total cholesterol; triglycerides; blood pressure; venous pCO 2 or pO 2 ; electrocardiograms; safety laboratory measures; or electrolyte disturbances. Metabolic acidosis was diagnosed in seven methazolamide-treated patients (five MET, two Non-MET) and no placebo patients. None of the patients with acidosis showed any clinically significant symptoms, and all remained on study (Supplementary Table 2). A greater proportion of patients in the methazolamide treatment arm (26 of 37 [70%]) reported adverse events (primarily respiratory tract infections and nausea) compared with placebo (23 of 39 [59%]). None of the adverse events were considered to be definitely related to study medication (Supplementary Table 3 ).
CONCLUSIONS
Methazolamide is the archetype for a potential new class of type 2 diabetes therapy. In addition to reducing HbA 1c , methazolamide provided unexpected additional clinical outcomes, including a rapid and persistent reduction in ALT and weight loss in metformin-cotreated patients. Type 2 diabetes is a risk factor for the development of liver diseases (4,5), and studies are ongoing to evaluate methazolamide liver effects on liver pathology.
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